Agios Pharmaceuticals, Inc. revenue
Agios Pharmaceuticals, Inc.'s revenue was $54.0m in fiscal 2025, up 48.0% on the year before. Since fiscal 2011 ($21.8m) it has grown at a compound 6.7% a year. Over the last twelve months it was $98.3m.
Revenue history
| Fiscal year | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22 | 25 | 26 | 65 | 59 | 70 | 43 | 94 | 118 | 0 | 0 | 14 | 27 | 36 | 54 | 98 |
| Growth on the year before | — | +15.0% | +1.8% | +155.8% | −9.5% | +18.2% | −38.5% | +119.4% | +24.9% | −100.0% | — | — | +88.4% | +36.1% | +48.0% | — |
| Gross profit | — | — | — | — | — | 70 | 43 | 93 | 117 | 0 | 0 | 13 | 24 | 32 | 48 | 90 |
| Gross margin | — | — | — | — | — | 100.0% | 100.0% | 98.5% | 98.9% | — | — | 88.0% | 89.3% | 88.6% | 88.3% | 92.0% |
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Agios Pharmaceuticals, Inc. | $98.3m | 140.6% | 69.6% |
| Septerna, Inc. | $98.9m | 13520.1% | — |
| Kymera Therapeutics, Inc. | $102m | 133.8% | 29.7% |
| Xencor Inc | $105m | -28.6% | -2.5% |
| 4d Molecular Therapeutics, Inc. | $92.0m | 278712.1% | 242.8% |
| Verastem, Inc. | $87.5m | 26.4% | 58.4% |
Compare with peers
- Septerna, Inc. revenue
- Kymera Therapeutics, Inc. revenue
- Xencor Inc revenue
- 4d Molecular Therapeutics, Inc. revenue
- Verastem, Inc. revenue
Head to head: AGIO vs SEPNAGIO vs KYMRAGIO vs XNCRAGIO vs FDMT
More: Biotechnology stocks compared, Health Care sector, rankings of US companies